Indonesia Oncology Drugs Market Analysis Report 2022 to 2030

Indonesia Oncology Drugs Market Analysis

$ 3999

By 2030, it is anticipated that the Indonesia oncology drugs market will reach a value of $xx Bn from $1.18 Bn in 2022, growing at a CAGR of xx% during 2022-2030. The oncology drug market in Indonesia is dominated by a few large pharmaceutical companies such as Bio Farma, Innogene by Kalbe Farma and Takeda Pharma. The oncology market in Indonesia is segmented into different therapeutic areas and different treatment types. The major factors affecting the Indonesian oncology drugs market are the increasing disease burden of non-communicable diseases like cancer and the lack of healthcare facilities for cancer treatment in most areas of Indonesia.

ID: IN10IDPH018 CATEGORY: Pharmaceuticals GEOGRAPHY: Indonesia AUTHOR: Dr. Vishwa Modhia

Buy Now

Indonesia Oncology Drugs Market Analysis Summary

By 2030, it is anticipated that the Indonesia oncology drugs market will reach a value of $xx Bn from $1.18 Bn in 2022, growing at a CAGR of xx% during 2022-30. In the last decade, Indonesia’s pharmaceutical market has been one of the fastest growing in the SEA region. The cost of healthcare per person in Indonesia increased from $87 in 2010 to $120 in 2021, but its share of GDP has stayed constant over the past ten years at 2.9%.

Nearly 70% of the disease burden currently results from non-communicable illnesses, such as cancer, and this percentage will rise as Indonesia completes its epidemiological transition. Equitable cancer care in Indonesia focuses primarily on reducing geographic disparities in healthcare infrastructure, human capital, and financial capacity, especially for the majority of the country's poor residents who reside in outlying/rural areas.

indonesia oncology drugs market analysis

Market Dynamics

Market Growth Drivers Analysis

Nearly 70% of all diseases, including cancer, are currently non-communicable, and as Indonesia completes its epidemiological transition, this percentage will rise. The number of incident cases of oncological conditions in Indonesia was estimated to be 396,000 in 2020, with breast cancer being the most prevalent followed by cervical cancer.

Market Restraints

The cost of proper healthcare (OOP system) and transportation to the referral secondary healthcare facilities are prohibitively expensive for cancer patients in remote areas of Indonesia, who also struggle to access cancer healthcare locally. In large parts of Indonesia, cancer healthcare services are underdeveloped and poorly organized.

Competitive Landscape

Key Players

Bio Farma (IDN)
Innogene by Kalbe Farma (IDN)
Sido Muncul (IDN)
Takeda (IDN)
Hoffmann-La Roche
Novartis
Gilead Sciences
Bayer

Regulations and Reimbursement

The Indonesian Food and Drug Authority, also known as Badan Pengawas Obat dan Makanan (Badan POM), is a crucial regulatory gatekeeper for the nation's use of drugs and vaccines. Approximately 82.3% of Indonesia's 270 Mn people are now covered by the National Healthcare Insurance (BPJS-JKN), including the poor (whose contributions are paid for by the government).

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Oncology Drugs Market Segmentation

By Drug class

Cytotoxic drugs
- Alkylating agents
- Antimetabolites
- Others
Targeted drugs
- Monoclonal antibodies
- Others
Hormonal drugs
Others

By Therapy

Chemotherapy
Targeted therapy
Immunotherapy

By Indication

Lung cancer
Stomach cancer
Colorectal cancer
Breast cancer
Prostate cancer
Others

By Dosage form

Solid
- Tablets
- Capsules
Liquid
Injectable
- Prefilled syringes
- Others

By Distribution channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
?Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.